ASCO Annual Meeting

Annual Meeting of American Society of Clinical Oncology (ASCO)

Chicago, June 4 - June 6, 2010

Investor Updates

  • Roche to Present New Data on Different Approaches To Treating Cancer at ASCO read more
  • Phase III study showed first-line maintenance use of MabThera doubles likelihood of people with follicular lymphoma living without their disease worsening read more
  • Roche Investor Event: ASCO 2010 read more
  • Roche presents early data on the next generation of therapeutic antibodies and other targeted therapies at ASCO read more
  • Phase III study showed Avastin-based regimen helped women with advanced ovarian cancer live longer without their disease worsening read more

More Information

Roche ASCO Planner

Invitation

ASCO coverage for media

Presentation Slides

Webcast

Analyst briefing on data presented at ASCO: Sunday, June 6

Download mp3 file

Highlights:

Setting the standard of care in oncology
Pascal Soriot, COO Roche Pharmaceuticals

Avastin in ovarian cancer, GOG-0218 study data
Jakob Dupont, M.D., M.A., Associate Group Medical Director Avastin Global ClinicalDevelopment, Genentech

Overview of Avastin development program
Stefan Frings, M.D., Ph.D., Avastin Franchise Director, Roche

MabThera/Rituxan maintenance in previously untreated patients with follicular lymphoma (PRIMA study)
Gilles Salles, M.D., Ph.D., Principal Investigator of PRIMA study Centre Hospitalier Lyon-Sud, France

Overview of Roche/Genentech oncology pipeline 
Hal Barron, M.D., Executive Vice President, Global Development and Chief Medical Officer, Roche